Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy

Chitra Lal
Charlie Strange

Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA

Abstract: COPD is characterized by persistent airflow obstruction caused by exposure to irritants including cigarette smoke, dust, and fumes. According to the latest GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines, a combination of inhaled corticosteroids, long-acting \( \beta_2 \) agonists, and long-acting muscarinic receptor antagonists can be used for group D COPD patients who are at high risk for exacerbations. Umeclidinium/fluticasone furoate/vilanterol is one such triple-combination therapy currently under development with some completed and several ongoing clinical trials. This review paper summarizes the pharmacologic profiles of these medications and highlights findings from clinical trials, including safety and efficacy data, while speculating on the role of this therapy in current treatment for COPD.

Keywords: COPD, umeclidinium, fluticasone furoate, vilanterol, triple therapy

Introduction

COPD is characterized by persistent airflow obstruction\(^1\) caused by exposure to irritants including cigarette smoke, dust, and fumes. To decrease the associated morbidity and mortality,\(^2\) there has been considerable interest in developing new medications for COPD. Given the regulatory barriers that are easiest to meet by improvement in lung function, the bulk of research is being directed towards the development of new bronchodilator and inhaled corticosteroid (ICS) medications.

According to the latest GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines,\(^3\) a combination of ICS, long-acting \( \beta_2 \) agonist (LABA), and long-acting muscarinic receptor antagonist (LAMA) can be used for group D COPD patients who are at high risk for exacerbations. Group D patients are symptomatic and usually have a forced expiratory volume in 1 second (FEV\(_1\)) of \(<50\%\) of the predicted value, two or more exacerbations within the last year, and/or one or more hospitalizations for COPD exacerbations. The recommendation is based on a few studies showing the superiority of the ICS/LAMA/LABA combinations\(^4,5\) as compared to monotherapy alone, in the level of bronchodilation, dyspnea score change, and use of rescue medications.

The concept of combining different bronchodilators in a single inhaler is an attractive one as it minimizes the number of COPD medications that the patient takes on a daily basis and thus may boost patient compliance. However, the challenge in combining medications of different classes in a single drug delivery device is ensuring the bio-stability of the individual compounds. Thus, while “open” triple-combination therapies such as tiotropium added to salmeterol/fluticasone and glycopyrronium added...
Inhaled VI is recommended at a dose of 25 μg. Studies of oral VI have shown it to be well tolerated up to doses of 500 μg as a single administration in healthy men. A study of inhaled VI in asthma at a dose of 25 μg once a day has shown it to be well tolerated with the commonest side effects reported being nasopharyngitis, headache, upper respiratory tract infection, and oropharyngitis. In yet another study conducted in healthy Japanese men, single inhaled doses of VI of 50 μg were found to be safe and well tolerated with no deaths or serious adverse events reported. Thus, the low dose of inhaled VI which is used therapeutically is unlikely to produce unexpected systemic toxicity in COPD patients.

FF is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. It is structurally related to fluticasone propionate, but with a distinct chemical and pharmacological profile. FF was found to be more potent than other glucocorticoids for preserving epithelial integrity and reducing epithelial permeability in response to protease- and mechanical-induced cell damage and was also found to have greater tissue retention than other glucocorticoids.

Pharmacokinetics of the triple therapy of UMEC/FF/VI has been studied in healthy volunteers. This triple therapy also called the “closed triple” is being developed by GSK and will be administered in a single inhaler (Ellipta® dry powder device).

Two single-center studies assessed the systemic exposure, systemic pharmacodynamics (PD), and safety profile of the closed triple therapy of UMEC/FF/VI compared with dual therapies. Healthy nonsmokers aged 18–65 years and with normal lung function were enrolled. Both studies were randomized, single-dose, crossover trials with study 1 being double-blind and study 2 being open-label. Participants were randomized to receive four consecutive inhalations (each administered as a single dose) via an Ellipta® dry powder inhaler in the following ways.

In study 1 (CTT116415/NCT01691547), FF/UMEC/VI at total doses of 400/500/100 μg, FF/UMEC 400/500 μg, UMEC/VI 500/100 μg, and FF/VI 400/100 μg were compared.

In study 2 (200587/NCT01894386), FF/UMEC/VI at total doses of 400/500/100 μg or 400/250/100 μg, FF/VI 400/100 μg, and UMEC/VI 250/100 μg were compared.

Of 88 subjects, 95% completed both studies. Total systemic exposure was similar for the triple therapy of UMEC/FF/VI compared with FF/VI and UMEC/VI. No clinically significant systemic PD findings were detected. The incidence of adverse events was low and similar across all treatment arms.

Thus, these studies showed that the closed triple therapy of UMEC/FF/VI was as safe as the currently marketed therapies of UMEC/VI (marketed as Anoro Ellipta) and FF/VI (marketed as Breo Ellipta). In addition, the systemic exposure to the individual components showed no clinically.
significant differences when administered as triple versus dual therapy.

**Clinical efficacy**

Two randomized studies have been conducted to study the safety and efficacy of UMEC added to FF/VI (NCT01957163; NCT02119286). Both of these were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies and evaluated the safety and efficacy of UMEC (62.5 and 125 µg) added to FF/VI (100/25 µg) in COPD. Patients (N=1,238) were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 µg, UMEC 125 µg, or placebo (PBO) added to open-label FF/VI 100/25 µg. Inclusion criteria were age ≥40 years, diagnosis of COPD, at least a 10 pack-years smoking history, pre- and post-salbutamol (albuterol), FEV₁/forced vital capacity ratio of <0.7 and predicted FEV₁ ≤70%, and a modified Medical Research Council dyspnea scale score ≥2. Subjects with asthma or other known respiratory disease, hospitalization in the prior 12 weeks for COPD or pneumonia, pregnancy, or use of long-term oxygen therapy were excluded.

The primary end point was trough FEV₁ on Day 85. The secondary end point was 0–6 hours post-dose weighted mean FEV₁ at Day 84. Quality of life was reported using St George’s Respiratory Questionnaire (SGRQ). In both studies, the primary and secondary end points were met; the trough FEV₁ was significantly improved on Day 85 with UMEC + FF/VI (62.5 and 125 µg) versus PBO + FF/VI (range: 0.111–0.128 L, P<0.001) as was 0–6 hours post-dose weighted mean FEV₁ on Day 84 (range: 0.135–0.153 L, P<0.001). Improvements in SGRQ were not seen consistently across both studies or with both doses of UMEC.

The overall incidence of adverse events was similar across all groups. Further details about adverse effects with the triple-combination therapy are included in the “Safety and tolerability” section.

There are some additional studies which are currently underway evaluating the safety and efficacy of the triple therapy of UMEC/FF/VI. These are listed in Table 2.

**Safety and tolerability**

The triple combination of UMEC/FF/VI has been found to be generally well tolerated. The commonest side effects reported include nasopharyngitis, headache, and back pain. Six total deaths were reported in both studies, NCT01957163 and NCT02119286, but were not considered related to the study treatment. Of note, all treatment regimens had both inhaled β agonists and corticosteroids, and therefore, side effect differences would only be expected for the variance in UMEC use and dose that were evaluated in primary licensing studies.

**Regulatory affairs**

Based on these successful clinical trials, GSK and Innoviva Inc. plan to file a new drug application in the US for the once-daily closed-triple-combination therapy, FF/UMEC/VI, for patients with COPD by the end of 2016. The companies expect an EU regulatory submission of the closed triple-combination therapy for COPD by the end of 2016 as well.

**Expert opinion**

One of the benefits of a triple combination of an ICS/LABA/LAMA is the potential improvement in patient compliance due to the need to take fewer inhalers. As triple therapy with ICS/LABA/LAMA is recommended for COPD patients at high risk for exacerbations, this should in turn translate into fewer COPD exacerbations, and consequently fewer COPD-related hospitalizations. This is particularly important since the number of inhalers filled on average in the US is <40% of that prescribed.

On the other hand, the need for continued steroid use in severe COPD patients with a history of exacerbations, on LABA and LAMA therapy, has been called into question. In a recent study, in patients with severe COPD on tiotropium + salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued ICS and those who continued ICS. There was, however, a greater decrease in lung function during the final step of glucocorticoid withdrawal.

Moreover, LABA/LAMA combination inhalers have been shown to be superior to LABA/ICS in one recent clinical trial, further calling into question the necessity of an inhaled ICS in COPD treatment regimens. Thus, while the initiation of triple therapy with ICS/LABA/LAMA in COPD patients at high risk for exacerbations is appropriate, the landscape of clinical use is changing.

The clinical explosion in use of the first long LABA/ICS combination salmeterol/fluticasone furoate (Advair) occurred at a time of limited competition. Although some physicians at the time predicted its failure since monotherapy of LABA and ICS was already available, the primary care physician community drove use. A medication that could define if dyspnea was likely of pulmonary airways origin was required. A medication that could define if dyspnea was likely of pulmonary airways origin was welcomed. In contrast, asthma guidelines patients are almost always responsive to combinations of any two components
of an LABA/LAMA/ICS regimen. Therefore, today many alternatives can give the same diagnostic value.

Because these drugs and their devices have been required to enter the US Food and Drug Administration clinical trials arena together, there still remains no generic long-acting bronchodilator on the US market. The major reason for non-compliance with inhaled medications for COPD is the cost of medication and/or copayments. With scheduled arrival of generic long-acting bronchodilators that will likely be less expensive within the life cycle of UMEC/FF/VI, few individuals believe that uptake will be rapid unless an aggressive price reduction from other combination bronchodilators accompanies the product launch.

Most of the current focus in drug development for COPD has been on producing newer bronchodilators or combining bronchodilators in the same drug delivery device.

**Table 2 Trials which are currently underway evaluating the safety and efficacy of the triple therapy of UMEC/FF/VI**

<table>
<thead>
<tr>
<th>Study and populations</th>
<th>Design</th>
<th>End points</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMPACT (InforMing the PAthway of COPD Treatment) study (NCT02164513)</td>
<td>Phase III double-blind, three-arm, parallel-group study for closed triple therapy</td>
<td>Co-primary end points: 1) annual rate of moderate and severe exacerbations comparing FF/UMEC/VI with FF/VI; and 2) annual rate of moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI</td>
<td>Pending</td>
</tr>
<tr>
<td>Target N=7,000 patients across 38 countries</td>
<td>Patients randomized to FF/UMEC/VI 100/62.5/25 µg, FF/VI 100/25 µg, or UMEC/VI 62.5/25 µg once daily for 52 weeks</td>
<td>Key secondary end points: 1) changes from baseline in trough FEV₁, comparing FF/UMEC/VI and FF/VI; 2) time to first moderate or severe exacerbation in all three arms of the study; and 3) annual rate of severe exacerbations in all three arms of the study</td>
<td>Improvements with FF/UMEC/VI compared to Symbicort® (budesonide/formoterol 400/12 µg) in: 1) trough FEV₁, (171 mL, 95% CI [148, 194], P&lt;0.001) and 2) SGRQ (−2.2 units, 95% CI [−3.5, −1.0], P&lt;0.001), at 24 weeks</td>
</tr>
<tr>
<td>FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed triple therapy) study (NCT02345161)</td>
<td>Phase III randomized, double-blind, double-dummy, parallel-group multicenter study evaluating once-daily closed triple therapy FF/UMEC/VI (100/62.5/25 µg)</td>
<td>Co-primary end point: change from baseline in trough FEV₁, and SGRQ total score after 24 weeks of treatment</td>
<td></td>
</tr>
<tr>
<td>Enrolled 1,810 patients across 162 study sites (911 on FF/UMEC/VI and 899 on budesonide/formoterol)</td>
<td>Inhalation powder versus twice-daily budesonide/formoterol (400/12 µg) via the Turbohaler dry powder inhaler</td>
<td>Secondary end points: 1) effect of FF/UMEC/VI on the annual rate of moderate or severe exacerbations compared with budesonide/formoterol; and 2) safety profile of FF/UMEC/VI compared with budesonide/formoterol over 24 and 52 weeks of treatment</td>
<td></td>
</tr>
<tr>
<td>NCT02731846</td>
<td>Phase III, 4 weeks, randomized, double-blind, parallel-group, multicenter study designed to assess the equivalence of closed triple therapy FF/UMEC/VI to open triple therapy (FF/VI + UMEC), with a comparison of both triple therapies to dual therapy (FF/VI) on lung function</td>
<td>Primary end point: change from baseline in trough FEV₁, on Day 29</td>
<td>Not yet enrolling</td>
</tr>
<tr>
<td>Target N=600</td>
<td>Secondary end points: 1) change from baseline in trough FEV₁, on Day 2 and Day 28; 2) change from baseline in trough FEV₁ on Days 2, 28, and 29; 3) change from baseline in weighted mean FEV₁, 0–6 hours on Day 1 and Day 28 (in a subset); and 4) serial FEV₁ over 0–6 hours on Day 1 and Day 28 (in a subset)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02729051</td>
<td>Phase IIIb, 24 weeks, randomized, double-blind, parallel-group multicenter study to compare the effect of FF/UMEC/VI with FF/VI + UMEC on lung function after 24 weeks</td>
<td>Primary end point: change from baseline in trough FEV₁ at 24 weeks</td>
<td>Currently enrolling</td>
</tr>
<tr>
<td>Target N=1,020</td>
<td>Key secondary end points: 1) proportion of responders based on SGRQ total score at Week 24; 2) change from baseline in SGRQ total score at Week 24; 3) proportion of responders based on TDI focal score at Week 24; 4) TDI focal score at Week 24; and 5) time to first moderate or severe exacerbation up to 27 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Abbreviations: UMEC, umeclidinium; FF, fluticasone furoate; VI, vilanterol; FEV₁, forced expiratory volume in 1 second; SGRQ, St George’s Respiratory Questionnaire; CI, confidence interval; TDI, transitional dyspnea index.
With failure of large trials to significantly change mortality in COPD despite enhancement of populations for cardiovascular disease, the use of LAMA/LABA/ICS medications is viewed at one level as an expenditure for quality-of-life improvements, particularly for dyspnea. Therefore, compliance with medication that is used for improving quality of life may fit within the domain of the patient.

The second indication that is outside of the patient domain is to decrease exacerbations that drive cost to both patients and hospital systems. As more health systems generate vertical models that require cost sharing for poor outcomes, the cost of triple-combination medications may be small in the relative cost of COPD. Therefore, the success of UMEC/FF/VI likely resides within health systems. For that reason, the upcoming studies on triple therapy for COPD exacerbation reduction compared to dual therapies are important. Until we can develop disease-modifying therapies for COPD, the inhaler world keeps getting more crowded with combinations of LABA, LAMA, and ICS preparations.

**Conclusion**

Current studies of the closed triple therapy of UMEC/FF/VI reveal it to be a promising new treatment for COPD patients who are at high risk for exacerbations. Additional studies are underway to further delineate the impact of this therapy on lung function, exacerbation frequency, and quality of life. This drug combination also appears to be safe and well tolerated. If approved for marketing, it will be an important addition to the treatment regimen for COPD, will boost patient compliance, and may decrease the risk of hospitalizations due to COPD exacerbations.

**Disclosure**

Dr Charlie Strange has current, past, or pending grants in COPD from the Alpha-1 Foundation, CSL Behring, Entera Health, Grifols, Shire, and the NIH. He consults for Abeona, AstraZeneca, CSL Behring, and Grifols, on COPD. Dr Chitra Lal has received grant support from Jazz Pharmaceuticals and Invaddo Pharmaceuticals and is a consultant for Ikaria Pharmaceuticals. The authors report no other conflicts of interest in this work.

**References**


